SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
International Reference Values for Total Pancreatectomy Show Higher Perioperative Risk Than Pancreatoduodenectomy — Practical Benchmarks for Quality Control
Posted inGeneral Surgery news Oncology

International Reference Values for Total Pancreatectomy Show Higher Perioperative Risk Than Pancreatoduodenectomy — Practical Benchmarks for Quality Control

This multicenter study defines international perioperative reference values for total pancreatectomy (TP). Even low‑risk TP carries higher morbidity and mortality than pancreatoduodenectomy; outcomes worsen with vascular resection or conversion for high‑risk anastomosis.
Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis
Posted inDiabetes & Endocrinology news Oncology

Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis

A 185-country study shows large, sustained increases in thyroid cancer incidence among adolescents and young adults (15–39 years) since the 2000s while mortality remains low and stable — a pattern most consistent with widespread overdiagnosis and overtreatment.
High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets
Posted innews Oncology Public Health

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets and improving treatment access could cut deaths by about a third.
Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults
Posted inHematology-Oncology news Oncology

Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults

A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and APL, and highlights dismal outcomes for patients ≥60 years.
Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05
Posted innews Oncology

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropenia but no treatment-related deaths.
Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies
Posted innews Oncology Public Health

Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies

Population-based Dutch data show that AYA survivors of most solid malignancies achieve five-year conditional relative survival >95% by four years post-diagnosis, supporting reconsideration of blanket 10‑year disclosure periods in Right to Be Forgotten laws.
Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
Posted innews Oncology

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxicity and overall tolerability.
One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand
Posted innews Oncology Otorhinolaryngology

One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand

Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue and dry mouth—with fear of cancer recurrence and ongoing analgesic use being the strongest correlates.
Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers
Posted innews Oncology Otorhinolaryngology

Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers

A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living concerns and associated with personal, clinical, lifestyle and health‑system factors.
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
Posted inDermatology news Oncology

Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma

The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short median times to recurrence or metastasis, substantial resource needs, and meaningful proportions of untreated metastatic episodes.